Articles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Current Editions
Search Archives
BCIQ
Company Profiles
Target Profiles
Product Profiles
Conferences
China Healthcare Summit
Bio€quity Europe
White Papers
Free Trial
/
Subscribe
Sign In
more_vert
Biocentury
Company Profiles
Target Profiles
Product Profiles
Free Trial Information
Export Pdf
Overview
Pipeline
Deals
Financings
Earnings Summary
Stock Summary
Articles
BioCentury
|
Dec 28, 2019
Financial News
Elpiscience’s $100M series B provides path to IPO
...IPO, Ming Fang, head of global BD, told BioCentury. New investors Tencent, GTJA Investment Group,
Dyee Capital
...
Read More
BioCentury
|
Oct 17, 2019
Financial News
Oct. 16 Financial Quick Takes: Hong Kong IPO could value Ascentage at $876M; plus Principia, Rhythm, ProQR, dMed, Ionova and Amarna
...in a series A round led by Lilly Asia Ventures, with participation from angel investor
Dyee Capital
...
Read More
Items per page:
10
1 - 2 of 2
BioCentury
|
Dec 28, 2019
Financial News
Elpiscience’s $100M series B provides path to IPO
...IPO, Ming Fang, head of global BD, told BioCentury. New investors Tencent, GTJA Investment Group,
Dyee Capital
...
Read More
BioCentury
|
Oct 17, 2019
Financial News
Oct. 16 Financial Quick Takes: Hong Kong IPO could value Ascentage at $876M; plus Principia, Rhythm, ProQR, dMed, Ionova and Amarna
...in a series A round led by Lilly Asia Ventures, with participation from angel investor
Dyee Capital
...
Read More
Items per page:
10
1 - 2 of 2
Previous page
Next page